SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mlrb2113 who wrote (320)11/11/2007 12:21:58 AM
From: Clarksterh  Read Replies (1) of 332
 
I think we might've underestimated the FDA. It's unusual for it to effectively stop a trial because of a safety issue, isn't it?

? I don't think the FDA stopped the trial. Just that the management talked to the FDA and came to the coordinated conclusion that they were highly unlikely to be approved for the higher dose. So why run the trials - expense and patient risk?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News